Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia-reperfusion in the mouse

International Journal of Cardiology

Volumn 209, Issue , 2016, Pages 215-220

  Toldo, Stefano ^a   Marchetti, Carlo ^a   Mauro, Adolfo G ^a   Chojnacki, Jeremy ^a   Mezzaroma, Eleonora ^a   Carbone, Salvatore ^a   Zhang, Shijun ^a   Van Tassell, Benjamin ^a   Salloum, Fadi N ^a   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Infarction; Inflammasome; Inflammation; Injury; Ischemia; Reperfusion

Indexed keywords

CARDIOVASCULAR AGENT; CRYOPYRIN; INTERLEUKIN 1BETA CONVERTING ENZYME; NLRP3 INHIBITOR; UNCLASSIFIED DRUG; INFLAMMASOME; NLRP3 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; HEART MUSCLE REPERFUSION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

ANIMALS; CARDIOVASCULAR AGENTS; INFLAMMASOMES; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84961695463     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.02.043     Document Type: Article

References (26)

1. K.A. Reimer, J.E. Lowe, M.M. Rasmussen, and R.B. Jennings The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs Circulation 56 1977 786 794
2. B. Ibanez, G. Heusch, M. Ovize, and F. Van de Werf Evolving therapies for myocardial ischemia/reperfusion injury J. Am. Coll. Cardiol. 65 2015 1454 1471
3. C. Marchetti, J. Chojnacki, S. Toldo, E. Mezzaroma, N. Tranchida, S.W. Rose, and et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse J. Cardiovasc. Pharmacol. 63 2014 316 322
4. S. Toldo, I.M. Seropian, E. Mezzaroma, B.W. Van Tassell, F.N. Salloum, E.C. Lewis, and et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury J. Mol. Cell. Cardiol. 51 2011 244 251
5. S. Toldo, D.G. Breckenridge, E. Mezzaroma, B.W. Van Tassell, J. Shryock, H. Kannan, and et al. Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse J. Am. Heart Assoc. 1 2012 e002360
6. E. Mezzaroma, S. Toldo, D. Farkas, I.M. Seropian, B.W. Van Tassell, F.N. Salloum, and et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse Proc. Natl. Acad. Sci. U. S. A. 108 2011 19725 19730
7. C. Marchetti, S. Toldo, J. Chojnacki, E. Mezzaroma, K. Liu, F.N. Salloum, and et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse J. Cardiovasc. Pharmacol. 66 2015 1 8
8. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N. Engl. J. Med. 357 2007 1121 1135
9. S. Toldo, E. Mezzaroma, A.G. Mauro, F. Salloum, B.W. Van Tassell, and A. Abbate The inflammasome in myocardial injury and cardiac remodeling Antioxid. Redox Signal. 22 2015 1146 1161
10. S. Toldo, E. Mezzaroma, M.D. McGeough, C.A. Pena, C. Marchetti, C. Sonnino, and et al. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart Cardiovasc. Res. 105 2015 203 212
11. W.M. Jong, J.C. Leemans, N.C. Weber, N.P. Juffermans, M.J. Schultz, M.W. Hollmann, and et al. Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression Int. J. Cardiol. 177 2014 41 43
12. Y. Liu, K. Lian, L. Zhang, R. Wang, F. Yi, C. Gao, and et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury Basic Res. Cardiol. 109 2014 415
13. A. Binder, A. Ali, R. Chawla, H.A. Aziz, A. Abbate, and I.S. Jovin Myocardial protection from ischemia-reperfusion injury post coronary revascularization Expert. Rev. Cardiovasc. Ther. 2015 1 13
14. G. Heusch Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning Circ. Res. 116 2015 674 699
15. K. Przyklenk Reduction of myocardial infarct size with ischemic "conditioning": physiologic and technical considerations Anesth. Analg. 117 2013 891 901
16. H. Kin, Z.Q. Zhao, H.Y. Sun, N.P. Wang, J.S. Corvera, M.E. Halkos, and et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion Cardiovasc. Res. 62 2004 74 85
17. I. Eitel, T. Stiermaier, K.P. Rommel, G. Fuernau, M. Sandri, N. Mangner, and et al. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial Eur. Heart J. 36 2015 3049 3057
18. D. De Paulis, P. Chiari, G. Teixeira, E. Couture-Lepetit, M. Abrial, L. Argaud, and et al. Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart Basic Res. Cardiol. 108 2013 379
19. L.O. Karlsson, N. Bergh, and L. Grip Cyclosporine A, 2.5 mg/kg, does not reduce myocardial infarct size in a porcine model of ischemia and reperfusion J. Cardiovasc. Pharmacol. Ther. 17 2012 159 163
20. T.H. Cho, P. Aguettaz, O. Campuzano, C. Charriaut-Marlangue, A. Riou, Y. Berthezene, and et al. Pre- and post-treatment with cyclosporine A in a rat model of transient focal cerebral ischaemia with multimodal MRI screening Int. J. Stroke 8 2013 669 674
21. S. Schaller, S. Paradis, G.A. Ngoh, R. Assaly, B. Buisson, C. Drouot, and et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition J. Pharmacol. Exp. Ther. 333 2010 696 706
22. D. Atar, H. Arheden, A. Berdeaux, J.L. Bonnet, M. Carlsson, P. Clemmensen, and et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results Eur. Heart J. 36 2015 112 119
23. O. Sandanger, T. Ranheim, L.E. Vinge, M. Bliksoen, K. Alfsnes, A.V. Finsen, and et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury Cardiovasc. Res. 99 2013 164 174
24. S. Deftereos, G. Giannopoulos, C. Angelidis, N. Alexopoulos, G. Filippatos, N. Papoutsidakis, and et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study Circulation 132 2015 1395 1403
25. A. Abbate, B.W. Van Tassell, S. Christopher, N.A. Abouzaki, C. Sonnino, C. Oddi, and et al. Effects of prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study) Am. J. Cardiol. 115 2015 8 12
26. B.W. Van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate Targeting interleukin-1 in heart disease Circulation 128 2013 1910 1923